ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 0299 • ACR Convergence 2022

    Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib

    Yoshiya Tanaka1, Tatsuya Atsumi2, Daniel Aletaha3, Robert Landewé4, Beatrix Bartok5, Alena Pechonkina6, Ling Han6, Kahaku Emoto7, Shungo Kano7, Vijay Rajendran8 and Tsutomu Takeuchi9, 1University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 2Hokkaido University, Sapporo, Japan, 3Medical University Vienna, Wien, Austria, 4Amsterdam University Medical Center, Meerssen, Netherlands, 5Gilead Sciences, Inc., La Jolla, CA, 6Gilead Sciences, Foster City, CA, 7Gilead Sciences, K.K., Tokyo, Japan, 8Galapagos NV, Gent, Belgium, 9Keio University and Saitama Medical University, Tokyo, Japan

    Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…
  • Abstract Number: 1057 • ACR Convergence 2022

    Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study

    Ivette Casafont-Solé1, Laura Calvo2, Anne Riveros-Frutos3, Carlos De la Puente Bujidos4, Pau Alcubilla5, Lourdes Mateo1 and Ivan Castellví6, 1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 4Ramon y Cajal University Hospital, Madrid, Spain, 5Hospital Clínic de Barcelona, Barcelona, Spain, 6Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: Pulmonary arterial hypertension (PAH) leads to a progressive right heart failure and death.PAH is a leading cause of death in Systemic Sclerosis (SSc). To…
  • Abstract Number: 1859 • ACR Convergence 2022

    Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody

    Jun Nakamura, Takao Nagashima and Kojiro Sato, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: Interstitial Lung Disease (ILD) accompanied with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is usually rapidly progressive and life-threatening with poor prognosis. Although…
  • Abstract Number: 0319 • ACR Convergence 2022

    Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy

    Daming Shao1, Alejandra Londoño Jimenez2, Maria Auxiliadora Salgado Guerrero3, Anna Broder4 and Shudan Wang5, 1Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 2McFarland Clinic, Ames, IA, 3University of Alabama at Birmingham, Birmingham, AL, 4Hackensack University Medical Center, Hackensack, NJ, 5Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
  • Abstract Number: 1130 • ACR Convergence 2022

    Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics

    Carlos Pérez-Sánchez1, Laura Muñoz-Barrera1, Tomás Cerdó2, Ismael Sánchez-Pareja2, Jerusalem Calvo-Gutierrez2, Rafaela Ortega-Castro1, Montserrat Romero-Gomez2, María Ángeles Aguirre-Zamorano3, María Carmen Ábalos-Aguilera4, Nuria Barbarroja1, José Perez-Venegas5, Mª Dolores Ruiz-Montesinos5, Carmen Dominguez5, Carlos Rodriguez-Escalera6, Carmen Romero-Barco6, Antonio Fernandez-Nebro7, Natalia Mena Vazquez7, Jose Luis Marenco8, Julia Uceda Montañez8, Charo Santos9, Eduardo Collantes1, Alejandro Escudero-Contreras2 and Chary Lopez-Pedrera1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 4Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, 5Virgen Macarena University Hospital, Sevilla, Spain, 6Virgen de la Victoria Hospital, Málaga, Spain, 7Regional University Hospital of Málaga, Málaga, Spain, 8Virgen de Valme University Hospital, Sevilla, Spain, 9Virgen de Valme University Hospital, Málaga, Spain

    Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…
  • Abstract Number: 1957 • ACR Convergence 2022

    Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis

    Nikolet den Hollander1, Marloes Verstappen2, Bastiaan van Dijk3, Annette van der Helm-van Mil4 and Hanna van Steenbergen3, 1Leids Universitair Medisch Centrum, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Centre (LUMC), Leiden, Netherlands, 4Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Undifferentiated arthritis (UA) is considered to be heterogenous and consists of subgroups, this notion is affirmed by differences in disease course, varying from spontaneous…
  • Abstract Number: 0328 • ACR Convergence 2022

    Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis

    Sarah Dyball1, Mia Rodziewicz1, Claudia Mendoza Pinto2, Ian N. Bruce3 and Ben Parker4, 1The University of Manchester, Manchester, United Kingdom, 2Systemic Autoimmune Diseases Research Unit, High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla, Mexico, 3Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 4Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

    Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…
  • Abstract Number: 1137 • ACR Convergence 2022

    MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy

    Kristin Wipfler1, Joshua Baker2 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene…
  • Abstract Number: 2022 • ACR Convergence 2022

    Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study

    Gregoire Martin de Fremont1, Nathalie Costedoat-Chalumeau2, Rakiba Belkhir3, Gaelle Guettrot-Imbert4, Nathalie Morel4, Gaetane Nocturne5, Anna Molto6, Tiphaine Goulenok7, Elisabeth Diot8, Estibaliz Lazaro9, Laurent Perard10, Nicole Ferreira11, Maelle Le Besnerais12, Nicolas Limal7, Nihal Martis13, Noémie Abisror14, Odile Debouverie15, Christophe Richez16, Vincent Sobanski17, Francois Maurier18, Gaetan Sauvetre12, Herve Levesque12, Marie Agnes Timsit19, Nathalie Tieule13, Pauline Orquevaux20, GEFA Collaborative group21, Matthieu Mahevas22, Celine Lartigau Roussin23, Elodie Chauvet24, Emilie Berthoux25, Francoise Sarrot Reynauld26, Loic Raffray27, Marion Couderc28, Nicolas Martin Silva29, Noemie Jourde Chiche30, Nicolas Belhomme31, Thierry Thomas32, Vincent Poindron33, Viviane Queyrel13, Juliette Delforge34, Camille Le Ray35, Emmanuelle Pannier35, Xavier Mariette36, Veronique Le Guern4 and Raphaèle Seror37, 1Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, 2Inserm DR Paris 5, Paris, France, 3Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 4Hôpital Cochin, Paris, France, 5APHP, Le Kremlin Bicêtre, France, 6Rheumatology Department, Cochin Hospital, APHP, Paris, France, 7APHP, Paris, France, 8CHU Tours, Tours, France, 9Bordeaux Hospital University, Bordeaux, France, 10CHU Lyon, Lyon, France, 11department of Internal Medecine, CHU de Tours, Tours, France, 12CHU Rouen, Rouen, France, 13CHU Nice, Nice, France, 14Hopital Saint Antoine, Paris, France, 15CHU Poitiers, Poitiers, France, 16Université de Bordeaux, Bordeaux, France, 17Université de Lille, Lille, France, 18Hôpitaux privés de Metz, Metz, France, 19CHU Brest, Brest, France, 20CHU Reims, Reims, France, 21Saint Joseph Hospital, Marseille, France, 22CHU Mondor, Creteil, France, 23CH La Réunion, CH la Réunion, France, 24CH Cabestany, Cabestany, France, 25CH Saint Joseph Saint Luc, Lyon, France, 26CHU Grenoble, CHU Grenoble, France, 27CH St Denis Reunion, Saint Denis Reunion, France, 28University Hospital, Clermont-Ferrand, France, 29CHU Caen, Caen, France, 30APHM, Marseille, France, 31CHU Rennes, Rennes, France, 32CHU Saint Etienne, Saint Etienne, France, 33Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 34Jean Verfier, Bobigny, France, 35Port Royal, Paris, France, 36Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 37University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
  • Abstract Number: 0329 • ACR Convergence 2022

    Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression

    Daniel Toro-Domínguez1, Manuel Martinez-Bueno1, Raúl López-Domínguez2, Jordi Martorell-Marugán1, Elena Carnero-Montoro1, Guillermo Barturen1, Daniel W. Goldman3, Michelle Petri3, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…
  • Abstract Number: 1154 • ACR Convergence 2022

    Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells

    Aneta Pekčcová1, Kristýna Bubová2, Monika Gregova3, Šárka Forejtová2, Jana Hořínková2, Markéta Hušáková2, Michal Tomcik4, Jindřiška Gatterová2, Jiří Vencovský5, Karel Pavelka6, Ladislav Šenolt5 and Jiří Baloun2, 1Institue of Rheumatology, Prague, Prague, Czech Republic, 2Institue of Rheumatology, Prague, Czech Republic, 3Institue of Rheumatology, Prague, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic

    Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs, which are essential for correct gene expression. The dysregulation in miRNA expression is accompanied by various diseases and…
  • Abstract Number: 2049 • ACR Convergence 2022

    ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
  • Abstract Number: 0432 • ACR Convergence 2022

    Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort

    Matthias Papo1, Pauline Martinot2, Renato A. Sinico3, Vitor Teixeira4, Nils Venhoff5, Maria-Letizia Urban6, Juliane Mahrhold7, Francesco Locatelli8, Giulia Cassone9, Franco Schiavon10, Benjamin Seeliger11, Thomas Neumann12, Claus Kroegel13, Matthieu Groh14, Chiara Marvisi15, Maxima Samson16, Thomas Barba17, David Jayne18, Arianna Troilo19, Jens Thiel20, Bernhard Hellmich21, Sara Monti22, Carlomaurizio Montecucco8, Carlo Salvarani23, Jean-Emmanuel Kahn24, Cecile-Audrey DUREL25, Luc Mouthon26, Loïc Guillevin26, Giacomo Emmi27, Augusto Vaglio28, Raphaël Porcher29 and Benjamin Terrier26, 1Service De Médecine Interne - Hôpital Cochin, Paris, France, 2Centre of Research in Epidemiology and Statistics, Université de Paris, Paris, Île-de-France, France, Paris, 3Department of Medicine and Surgery, Università degli Studi di Milano – Bicocca, Italy, Milano, Italy, 4Hospital de Faro, CHUA, Lisbon, Portugal, 5Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 6Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy, 7Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, 8Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, 9Università di Modena e Reggio Emilia, Modena, Italy, 10Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, 11Department of Respiratory Medicine, Hannover Medical School, Wermsdorf, Germany, 12Kantonsspital St. Gallen, St. Gallen, Switzerland, 13Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, 14Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, 15Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, 16Dijon University Hospital, Dijon, France, 17Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, 18University of Cambridge, Cambridge, United Kingdom, 19Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 20University Hospital Freiburg, Freiburg, Germany, 21Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 22Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, 23Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, 24Service de médecine interne - Hôpital Ambroise Paré, AP-HP, Boulogne-Billancourt, France, 25CHU Lyon, Lyon, France, 26National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 27Azienda Ospedaliero Universitaria Careggi, Firenze, Italy, 28Azienda Ospedaliero Universitaria Meyer, Parna, Italy, 29Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) frequently control the…
  • Abstract Number: 1262 • ACR Convergence 2022

    Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis

    Irina Gessl1, Thomas Deimel1, Paul Studenic1, Giorgio Tamborrini2, Pascal Zufferey3, Daniel Aletaha4, Burkhard Moeller5 and Peter Mandl1, 1Medical University of Vienna, Vienna, Austria, 2Ultrasound Center and Institute for Rheumatology, Zürich, Switzerland, 3HFR, Fribourg, Switzerland, 4Medical University Vienna, Wien, Austria, 5Inselspital - University Hospital Bern, Bern, Switzerland

    Background/Purpose: Musculoskeletal ultrasound (US) has been reported to predict radiographic progression in rheumatoid arthritis (RA). The aim of the study was to test the predictive…
  • Abstract Number: 2204 • ACR Convergence 2022

    Interosseous Tendon Inflammation in the Hands: A Novel Feature of Developing Rheumatoid Arthritis? Results from a Large MRI Study in Clinically Suspect Arthralgia

    Bastiaan van Dijk1, Hanna van Steenbergen1, Monique Reijnierse2, Sarah J.H. Khidir2, Lambertus Wisse1, Marco deRuiter1 and Annette van der Helm-van Mil3, 1Leiden University Medical Centre (LUMC), Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Inflammation around the tendons of hand interosseous muscles (interosseous tendon inflammation; ITI) on MRI was recently reported for the first time in rheumatoid arthritis…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology